Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00044356 · ClinicalTrials.gov registry record · Phase 2
Phase II Trial of Allovectin-7® for Metastatic Melanoma
A Phase 2 study of Melanoma and Metastatic Melanoma, sponsored by Vical.
- Completed
- Registry status
- Phase 2
- Development phase
- 133
- Enrollment target
- 16
- Study locations
NCT00044356: Completed Phase 2 study of Melanoma and Metastatic Melanoma, sponsored by Vical.
NCT00044356 is a Phase 2 study of Melanoma and Metastatic Melanoma that has completed, run by Vical. The registered enrollment target is 133 participants, below the 706-participant average among 266 other Melanoma trials with a reported enrollment target (81% lower). The trial reports 16 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00044356, a Phase 2 study of Melanoma and Metastatic Melanoma, has completed, sponsored by Vical.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 133 participants
- Enrollment target
- 16
- Study locations
Study Summary
The purpose of this clinical trial is to determine if Allovectin-7®, an experimental gene-based immunotherapy, can shrink melanoma tumors. The trial will also examine if this treatment can improve the time to disease progression.
Conditions Studied
Interventions
- GENETIC Allovectin-7®
Study Locations (16)
California
- Comprehensive Blood and Cancer Center - Bakersfield
- University of California, San Francisco - San Francisco
Minnesota
- North Memorial Health Care - Robbinsdale
- Mayo Clinic - Rochester
Arizona
- Arizona Cancer Center - Tucson
Arkansas
- University of Arkansas Cancer Research Center - Little Rock
Colorado
- University of Colorado Cancer Center - Denver
Illinois
- Oncology Specialists, S.C. - Park Ridge
Louisiana
- Louisiana State University Medical Center - New Orleans
Maryland
- Hematology Oncology Associates of Baltimore - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 133 participants |
| Start Date | 2001-02 |
| Est. Completion | 2004-09 |
| Phase | Phase 2 |
What the finished NCT00044356 record still lists
NCT00044356 is an interventional study that assigns participants to a tested intervention. The registered 133 participants enrollment target is mid-sized for trials with a published cap, below the 706-participant average among 266 other Melanoma trials with a reported enrollment target (81% lower).
The record links to 4 conditions, with Melanoma appearing as the primary indexed condition, and to 1 intervention - of which Allovectin-7® is the first listed.
NCT00044356 lists 16 locations in 14 states (California, Minnesota, Arizona).
Frequently Asked Questions
What is clinical trial NCT00044356 about?
NCT00044356 is a clinical study titled "Phase II Trial of Allovectin-7® for Metastatic Melanoma". The purpose of this clinical trial is to determine if Allovectin-7®, an experimental gene-based immunotherapy, can shrink melanoma tumors. The trial will also examine if this treatment can improve the time to disease progression.
What is the current status of trial NCT00044356?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 133 participants. The study started on 2001-02. Estimated completion is 2004-09.
What conditions does trial NCT00044356 study?
This clinical trial studies the following conditions: Melanoma, Metastatic Melanoma, Skin Cancer, Malignant Melanoma.
What interventions are being tested in trial NCT00044356?
The interventions under investigation include: Allovectin-7® (GENETIC).
Who is sponsoring clinical trial NCT00044356?
This trial is sponsored by Vical, which has 13 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00044356 being conducted?
This trial has 16 study locations across Arizona, Arkansas, California, Colorado, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Melanoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00044356's enrollment target sits among peer trials
133 97th of 266 higher than 170 of 266 other Melanoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Melanoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies
RECRUITING · Phase 2
-
Neoadjuvant Immune Checkpoint Blockade + a Prebiotic Food-enriched Dietary Intervention to Optimize Immune Response in Melanoma: NEO-PreFED
RECRUITING · Phase 2
-
Zimberelimab (AB122) With TIGIT Inhibitor Domvanalimab (AB154) in PD-1 Relapsed/Refractory Melanoma
RECRUITING · Phase 2
-
A Study of IBI363 in Subjects with Advanced Solid Malignancies
RECRUITING · Phase 2
-
A Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab
RECRUITING · Phase 2
-
Neoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04276870 · 133 participants · Phase 2
Orphan Indications for CD19 Redirected Autologous T Cells
- NCT04671771 · 133 participants · NA
A Study to Evaluate the Safety and Effectiveness of the InnAVasc Arteriovenous Graft for Hemodialysis Access in Patients With End-Stage Renal Disease
- NCT05610085 · 133 participants · Phase 2
A Dose Escalation Study of Levetiracetam in the Treatment of Neonatal Seizures
- NCT06206486 · 133 participants
The Gut Microbiome and Serum Metabolites As a Biological Mechanism Underlying Pain in Kidney Transplantation
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia